Compare PARK & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | XBIT |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | United States | United States |
| Employees | 1212 | N/A |
| Industry | Misc Health and Biotechnology Services | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 75.0M |
| IPO Year | N/A | 2015 |
| Metric | PARK | XBIT |
|---|---|---|
| Price | $17.70 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.4K | ★ 22.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.29 | $2.09 |
| 52 Week High | $21.60 | $3.61 |
| Indicator | PARK | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 62.82 |
| Support Level | $15.56 | $2.29 |
| Resistance Level | $17.69 | $2.69 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 19.61 | 64.00 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.